Overlaps in molecular lesions. Schematic representation of the distribution of molecular lesions across diseases. For example, in ET (yellow shape), 50% of patients have a JAK2-V617F mutation (red area, right part of the panel), whereas 50% are V617F-negative (white area) or display a mutation different from JAK2-V617F (green area, left part of the panel). Among JAK2-positive ET patients, the majority have a low allele burden (median around 20%), but a few may have a higher allele burden. In PV (red shape), the majority of patients are positive for the JAK2-V617F mutation, with a higher median allele burden (approximately 50%). In PMF, approximately 60% of patients are JAK2-V617F positive, with a high allele burden (often above 50%). Other mutations include: MPL, JAK2-exon 12, TET2, ASXL1, LNK, CBL, EZH2, SOCSs, IDHs, p53, NRAS, NF1, IKZF1, RUNX1, and RB. V617F-neg indicates the absence of the JAK2-V617F mutation; V617F-pos, the presence of the JAK2-V617F mutation.